30 research outputs found

    Torsional behaviour of rectangular hollow sections.

    Get PDF
    The results of a series of full-scale torsion tests on rectangular hollow sections (RHS) are presented and discussed. The observed torque–twist behaviour is compared to that predicted by an extended version of Marshall’s simplified thick wall torsion theory and finite element (FE) analysis, and significant differences are highlighted and examined. The behaviour predicted by the FE models is shown to be identical to that predicted by Marshall’s thick wall theory, which forms the basis of the British and European design procedures. However, even though the experimental measurements agree with the FE and theoretical predictions in the elastic range, the measurements of torsional capacity are significantly lower than those calculated, and this has important implications for design that may be wider than just torsion of RHS. A number of potential causes for this behaviour are examined, but it is yet to be fully explained. Evidence of similar behaviour in previous large-scale testing is highlighted and discussed

    Properties of UK-Grown Sitka Spruce: Extent and Sources of Variation.

    Get PDF
    Structural timber produced from Sitka spruce plantations in the UK typically achieves the requirements for the C16 strength class. However, very little is known about the variability of this plantation resource, or the factors that contribute to this variability. A study to benchmark the properties of the current resource found that there was a considerable amount of variation in wood properties between sites as well as between trees within a site. This benchmarking study has been complemented by studies which have investigated the impacts of genetics, precommercial thinning and rotation length on timber properties. In these studies, measurements of stress wave velocity have been made on standing trees, freshly-felled logs and sawn timber. Knowledge gained should assist in better utilisation of the current resource as well as identifyingmanagement practices that will lead to an improved future resource for structural applications

    Properties of UK-Grown Sitka Spruce: Extent and Sources of Variation.

    Get PDF
    Structural timber produced from Sitka spruce plantations in the UK typically achieves the requirements for the C16 strength class. However, very little is known about the variability of this plantation resource, or the factors that contribute to this variability. A study to benchmark the properties of the current resource found that there was a considerable amount of variation in wood properties between sites as well as between trees within a site. This benchmarking study has been complemented by studies which have investigated the impacts of genetics, precommercial thinning and rotation length on timber properties. In these studies, measurements of stress wave velocity have been made on standing trees, freshly-felled logs and sawn timber. Knowledge gained should assist in better utilisation of the current resource as well as identifyingmanagement practices that will lead to an improved future resource for structural applications

    Strategic Integrated Research in Timber: Getting the most out of the UK's timber resource.

    Get PDF
    Sitka spruce (Picea sitchensis) is the United Kingdom’s main commercial tree species accounting for nearly one-third of the UK's total woodland area and half of its conifer estate. Sawn timber from this species readily grades to the C16 strength class, but there are factors beyond the structural grade that can influence its acceptance as a construction material. This paper summarises the results from resource characterisation studies that have investigated the properties of Sitka spruce at the standing-tree scale down to the scale of a few microns. These studies have substantially improved the understanding of the impact on mechanical performance of structural timber of factors at the micro-structural level (e.g. cellulose structure and abundance) and at the forest-level (e.g. genetics, the environment and forest management). End-user requirements for timber are discussed in terms of what is, and is not, provided by current grading practice and some of the main misconceptions about UK-timber are challenged

    Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries.

    Get PDF
    BACKGROUND: As global initiatives increase patient access to surgical treatments, there remains a need to understand the adverse effects of surgery and define appropriate levels of perioperative care. METHODS: We designed a prospective international 7-day cohort study of outcomes following elective adult inpatient surgery in 27 countries. The primary outcome was in-hospital complications. Secondary outcomes were death following a complication (failure to rescue) and death in hospital. Process measures were admission to critical care immediately after surgery or to treat a complication and duration of hospital stay. A single definition of critical care was used for all countries. RESULTS: A total of 474 hospitals in 19 high-, 7 middle- and 1 low-income country were included in the primary analysis. Data included 44 814 patients with a median hospital stay of 4 (range 2-7) days. A total of 7508 patients (16.8%) developed one or more postoperative complication and 207 died (0.5%). The overall mortality among patients who developed complications was 2.8%. Mortality following complications ranged from 2.4% for pulmonary embolism to 43.9% for cardiac arrest. A total of 4360 (9.7%) patients were admitted to a critical care unit as routine immediately after surgery, of whom 2198 (50.4%) developed a complication, with 105 (2.4%) deaths. A total of 1233 patients (16.4%) were admitted to a critical care unit to treat complications, with 119 (9.7%) deaths. Despite lower baseline risk, outcomes were similar in low- and middle-income compared with high-income countries. CONCLUSIONS: Poor patient outcomes are common after inpatient surgery. Global initiatives to increase access to surgical treatments should also address the need for safe perioperative care. STUDY REGISTRATION: ISRCTN5181700

    Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function

    Get PDF
    Background: Cardiovascular disease is a major comorbidity of rheumatoid arthritis (RA) and a leading cause of death. Chronic systemic inflammation involving tumour necrosis factor alpha (TNF) could contribute to endothelial activation and atherogenesis. A number of anti-TNF therapies are in current use for the treatment of RA, including certolizumab pegol (CZP), (Cimzia ®; UCB, Belgium). Anti-TNF therapy has been associated with reduced clinical cardiovascular disease risk and ameliorated vascular function in RA patients. However, the specific effects of TNF inhibitors on endothelial cell function are largely unknown. Our aim was to investigate the mechanisms underpinning CZP effects on TNF-activated human endothelial cells. Methods: Human aortic endothelial cells (HAoECs) were cultured in vitro and exposed to a) TNF alone, b) TNF plus CZP, or c) neither agent. Microarray analysis was used to examine the transcriptional profile of cells treated for 6 hrs and quantitative polymerase chain reaction (qPCR) analysed gene expression at 1, 3, 6 and 24 hrs. NF-κB localization and IκB degradation were investigated using immunocytochemistry, high content analysis and western blotting. Flow cytometry was conducted to detect microparticle release from HAoECs. Results: Transcriptional profiling revealed that while TNF alone had strong effects on endothelial gene expression, TNF and CZP in combination produced a global gene expression pattern similar to untreated control. The two most highly up-regulated genes in response to TNF treatment were adhesion molecules E-selectin and VCAM-1 (q 0.2 compared to control; p > 0.05 compared to TNF alone). The NF-κB pathway was confirmed as a downstream target of TNF-induced HAoEC activation, via nuclear translocation of NF-κB and degradation of IκB, effects which were abolished by treatment with CZP. In addition, flow cytometry detected an increased production of endothelial microparticles in TNF-activated HAoECs, which was prevented by treatment with CZP. Conclusions: We have found at a cellular level that a clinically available TNF inhibitor, CZP reduces the expression of adhesion molecule expression, and prevents TNF-induced activation of the NF-κB pathway. Furthermore, CZP prevents the production of microparticles by activated endothelial cells. This could be central to the prevention of inflammatory environments underlying these conditions and measurement of microparticles has potential as a novel prognostic marker for future cardiovascular events in this patient group. Disclosure statement: Y.A. received a research grant from UCB. I.B. received a research grant from UCB. S.H. received a research grant from UCB. All other authors have declared no conflicts of interes

    Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

    Get PDF
    BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment
    corecore